Name: Marie Svedberg
Title: Professor
Department: Department of Health Sciences
Phone: +46(0)8 – 587 516 44
E-mail: marie.svedberg@rkh.se
ORCID: 0000-0002-1075-8515
Dissertation year: 2005
Thesis: Regulatory mechanisms and plasticity of nicotinic receptors in transgenic mice overexpressing human beta-amyloid (APPswe) and acetylcholinesterase: implications for Alzheimer’s disease
Link to thesis: https://openarchive.ki.se/xmlui/handle/10616/43402
ResearchGate: https://www.researchgate.net/profile/Marie-Svedberg
Linked in: https://www.linkedin.com/in/marie-svedberg-93149a5a/
About me
I have a master’s degree in Pharmaceuticals Sciences and have a dedicated interest in medical research. In 2005, I defended my thesis at Karolinska Institutet, focusing on receptor pharmacology and Alzheimer's disease. Following my PhD, I completed postdoctoral projects where I was introduced to neuroimaging techniques, including positron emission tomography (PET), and worked on developing potential biomarkers to visualize disease processes in the brain.
Subsequently, I worked as a senior lab manager at Karolinska Institutet, participating in numerous research projects focused on neurological diseases and neuropsychiatric conditions such as depression and bipolar disorder. In 2018, I was appointed associate professor in medical science and gained experience teaching at both undergraduate and advanced levels. Today, I work as an professor of medicine at the Swedish Red Cross University.
Research profile
My research focus is on neuropsychiatric and neurodegenerative conditions. The goal is to identify associations between various biological markers and the structural changes observed in patients with these conditions. Studying biomarkers is crucial for several reasons. Neurodegenerative disorders are often preceded by a long preclinical phase when changes in the brain occur and develops gradually, but the patient have no clinical symptoms. In this early phase of the disease, diagnostic biomarkers are especially valuable for diagnosis. An early diagnosis increases the potential for early intervention and treatment, which can slow disease progression and improve the quality of life for these patients.
Additionally, my research aims to gain a deeper understanding of how various risk factors, lifestyle factors, and pharmacological treatment affect individuals with long-term health conditions. Several drugs used to treat symptoms of neurodegenerative conditions are inappropriate for the elderly. Registry-based studies can be used to investigate the effects and side effects of commonly prescribed medications in elderly and frail patients. By comparing different health outcomes, the goal is to enhance knowledge regarding treatment guidelines.
In conclusion, my research aims to contribute to improved and more individualized care and treatment strategies for the elderly with multimorbidity, polypharmacy, and increased care needs.
Brief facts
- PhD Karolinska Institutet, 2005
- Subject area of competence; Medical Sciences, anatomy and physiology, neuroscience, neurodegenerative disorders, neuroimaging, pharmacology
- Author of approximately 50 scientific articles
- Former supervisor of three PhD students
Publications
Kullenberg H, Rossen J, Johansson UB, Hagströmer M, Nyström T, Kumlin M & Svedberg MM. (2024) Correlations between insulin-degrading enzyme and metabolic markers in patients diagnosed with type 2 diabetes, Alzheimer's disease, and healthy controls: a comparative study. Endocrine
https://pubmed.ncbi.nlm.nih.gov/37980298/
Kullenberg H, Wibom M, Kumlin M, Nyström T & Svedberg MM. (2023) Associations Between the Use of Metformin and Behavioral and Psychological Symptoms in Patients with Alzheimer´s Disease, and Type 2 Diabetes Mellitus - a Register-Based Study. Current Alzheimer Research
https://pubmed.ncbi.nlm.nih.gov/37221687/
Nordström A, Jangard M, Svedberg M, Ryott M & Kumlin M. (2022) Levels of eicosanoids in nasal secretions associated with nasal polyp severity in chronic rhinosinusitis. Prostaglandins, Leukotrienes and Essential Fatty Acids
https://pubmed.ncbi.nlm.nih.gov/35917595/
Kullenberg H, Rossen J, Johansson UB, Hagströmer M, Nyström T, Kumlin M & Svedberg MM. (2022) Increased levels of insulin-degrading enzyme in patients with type 2 diabetes mellitus. Endocrine
https://pubmed.ncbi.nlm.nih.gov/35751775/
Veldman E, Varrone A, Varnäs K, Svedberg MM, Cselenyi Z, Tiger M, Gulyas B, Halldin C & Lundberg J. (2022) Serotonin 1B receptor density mapping of the human brainstem using Positron Emission Tomography and Autoradiography. Journal of Cerebral Blood Flow and Metabolism
https://pubmed.ncbi.nlm.nih.gov/34644198/
Nordström A, Jangard M, Svedberg M, Kullenberg H, Ryott M & Kumlin M. (2022) Hot saline irrrigation in comparison to nasal packing after sinus surgery. Laryngoscope Investing Otolaryngology
https://pubmed.ncbi.nlm.nih.gov/34938861/
Svedberg MM, Varnäs K, Varrone A, Mitsios N, Mulder J, Gulyás B, Beaumont V, Munoz-Sanjuan I, Zaleska MM, Schmidt CJ, Halldin C & Mrzljak L. (2029) In vitro phosphodiesterase 10A (PDE10A) binding in whole hemisphere human brain using the PET radioligand [18F]MNI-659. Brain Research
https://www.ncbi.nlm.nih.gov/pubmed/30664847
Veldman E, Svedberg MM, Svenningsson P, & Lundberg J. (2017) Distribution and levels of 5-HT1B receptor in anterior cingulate cortex of patients with bipolar disorder, major depression and schizophrenia – an autoradiographic study. European Neuropsychopharmacology
https://www.ncbi.nlm.nih.gov/pubmed/28318898
Veldman E, Jia Z, Halldin C & Svedberg MM. (2026) Amyloid binding properties of curcumin analogues in Alzheimer´s disease postmortem brain tissue. Neuroscience Letters
https://www.ncbi.nlm.nih.gov/pubmed/27461789
Svedberg MM, Rahman O & Hall H. (2012) Preclinical studies of potential amyloid binding PET/SPECT ligands in Alzheimer’s disease. Nuclear Medicine and Biology
http://www.ncbi.nlm.nih.gov/pubmed/22226025
Svedberg MM, Hall H, Hellström-Lindahl E, Estrada S, Guan Z, Nordberg A & Långström B. (2009) [11C]PIB-amyloid binding and levels of Aβ40 and Aβ42 in postmortem brain tissue from Alzheimer patients. Neurochemistry International
http://www.ncbi.nlm.nih.gov/pubmed/19162107